Project Grant R01DA066665
Award Date 8/1/26
Completion Date 5/31/31
Dollars Obligated $721K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $181,092 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate dopamine receptor type 2 (D2)-expressing cells in the ventral hippocampus and their role in cocaine relapse vulnerability. The research comprises three aims conducted in New York, NY through April 30, 2028. Aim 1 characterizes ventral hippocampus D2 neuron activity during cocaine intravenous...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $796,299 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct single chromatin fiber multiomic mapping in opioid use disorder brain tissue. The recipient will perform genome-wide profiling of chromatin organization directly from frontal and cingulate cortex nuclei obtained from donors with chronic opioid use disorder. The work charts nucleosomal array organization,...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $2.352 million on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct single-molecule functional validation of neurogenomic alterations in opioid-exposed HIV brain tissue. The project performs single-molecule fiber-seq profiling on cingulate cortex tissue samples from the SCORCH (Single Cell Opioid Response in the Context of HIV) consortium, analyzing approximately...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $2.35 million on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to mine transcriptomic datasets and resolve functionally relevant striatal cell types in response to HIV infection and opioid use. The recipient will analyze single-nucleus RNA sequencing, two-dimensional single-cell spatial transcriptomic, and three-dimensional single-cell spatial transcriptomic data generated...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $100,228 on October 8, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on opioid reward mechanisms. The award funds a project investigating the functional role of a novel cortical circuit connecting the dorsal peduncular nucleus to the ventral tegmental area in mediating opioid reward. The research employs barcoded anatomy resolved by sequencing combined with spatial...
- The National Institute on Drug Abuse awarded Boston Children's Hospital $800,131 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the functions and mechanisms of a molecularly defined prefrontal cortex neuron subtype in drug addiction. The research focuses on identifying and characterizing POU3F1-expressing layer 5 neurons in the prefrontal cortex and their role in regulating cocaine-seeking behavior. The work employs single-cell RNA sequencing...
- The National Institute on Drug Abuse awarded Vanderbilt University $236,664 on September 25, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate how cocaine self-administration differentially alters neural encoding of drug and non-drug reinforcers in the nucleus accumbens. The research uses cellular-resolution imaging with microendoscopes to record single-cell neural activity in awake and behaving animals in response to both cocaine and sucrose, tracking how...
- The National Institute on Drug Abuse awarded $675,247 to Texas A&M University System Health Science Center on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate how cocaine exposure disrupts cognitive flexibility through cholinergic dysregulation in the dorsomedial striatum. The project examines cocaine-induced alterations in medium spiny neurons and cholinergic interneurons, focusing on three specific aims. Aim 1 defines how enhanced inhibition...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai a cooperative agreement valued at $749,153 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a phased, randomized, double-blind clinical trial testing transcranial direct current stimulation (tDCS) over the right dorsolateral prefrontal cortex to reduce craving and cue reactivity in patients with opioid use disorder. The study will randomize 60 inpatients with...
- The National Institute on Drug Abuse, a component of the Department of Health and Human Services, awarded Drexel University $684,123 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the role of inflammasomes in the neurobehavioral and transcriptomic effects of cocaine exposure and HIV infection. The research addresses cocaine use disorder in people living with HIV, a population experiencing exacerbated risk for behavioral and cognitive deficits...